
AstraZeneca is expected to generate almost $600 million from just two drug sales: Zoming, a migraine therapy, and Seloken, a …

AstraZeneca announced that it had sold the European rights to its drug, Seloken (metoprolol), to Italian pharmaceutical company Recordati. The …
NIHR chief scientific adviser visits Huddersfield health innovation campus
One in three UK women with migraine say symptoms taken less seriously
Report highlights scope to expand day surgery
Sygnature formalises drug discovery collaboration with X-Chem
Codis appoints Steven Facer as chief commercial officer

